Biomaterials

Biomaterials are materials designed to sit inside or against living tissue and do a job there—replace a hip, hold a suture, carry a drug, scaffold a regrowing artery.

8 frameworks, from 1940 to today · Biomedical Engineering · Engineering

still a working view ended · each leads to its entry below

Overview

Biomaterials are materials designed to sit inside or against living tissue and do a job there—replace a hip, hold a suture, carry a drug, scaffold a regrowing artery1. The field's central problem is unlike that of ordinary materials engineering: the body is a chemically aggressive, mechanically demanding, immunologically vigilant environment that attacks almost everything foreign. A material that is strong enough for a load-bearing implant may corrode; one that is perfectly inert may be walled off in a fibrous capsule; one that dissolves may dissolve too fast. The history of biomaterials is the history of how practitioners learned to think about that conflict—first by trying to make materials the body would ignore, then by making materials the body would accept, then by making materials that would actively instruct the body to heal.

From surgical craft to materials science: metals, sutures, and the first implants

Materials have been placed in bodies for as long as surgery has existed. Gold wire for dental work and catgut sutures—twisted animal intestine that the body slowly digests—are ancient. But the modern field begins when surgeons and engineers started asking systematic questions about what a material does inside tissue, rather than only whether it holds.

The decisive early case was the metallic bone implant. By the late nineteenth and early twentieth centuries, surgeons were plating fractures with steel; the plates often corroded, loosened, and caused pain. The problem was electrochemical: different metals in contact with body fluid, which is a salt solution, form a galvanic cell, and the implant itself becomes an electrode. The insight that a single, corrosion-resistant metal was needed led to the adoption of stainless steels and, in the mid-twentieth century, to titanium and its alloys. Titanium's oxide layer, which forms spontaneously and re-forms when scratched, made it unusually well tolerated in bone—the phenomenon later called osseointegration, observed in the 1950s and 1960s in the work of Per-Ingvar Brånemark on titanium chambers in rabbit bone, which became the basis of modern dental implants.

The parallel development was in polymers. PMMA (poly(methyl methacrylate)), an acrylic, was used as a denture base and, from the 1950s–60s, as bone cement to fix joint replacements. Silicones entered the body as shunts and tubing. The first successful total hip replacement, developed by John Charnley in England in the early 1960s, was as much a materials system as a surgical procedure: a stainless-steel stem, a polyethylene socket, and acrylic bone cement, each chosen for a different combination of strength, low friction, and fixation.

The inert paradigm: making the body ignore the material

Through the mid-twentieth century, the guiding idea was inertness. If a material did not react with tissue, the reasoning went, the body would tolerate it. Practitioners screened candidates by corrosion resistance, leached-ion toxicity, and mechanical match, and the field's standard test was the absence of reaction: a "biocompatible" material was one that provoked only a thin, quiet fibrous capsule.

This paradigm produced durable devices—vascular grafts of woven Dacron and expanded PTFE, heart-valve housings, pacemaker leads—but it also had a blind spot. The body does not simply ignore foreign objects. It recognizes them, and it responds. The fibrous capsule that the inert paradigm treated as success was itself a wound-healing response, and over years it could contract, calcify, or isolate the implant from the tissue it was meant to serve. The paradigm also could not explain why some materials failed in ways that had nothing to do with bulk chemistry: blood clotting on a polymer surface, for instance, was a surface event, not a bulk one.

The blood–material interface

Blood forced the field to think at the surface. When blood contacts a synthetic surface, plasma proteins adsorb within seconds, platelets adhere and activate, and the coagulation cascade can be triggered—producing thrombus on a graft or valve. The problem was acute for cardiovascular devices, and it drove a distinct line of work: hemocompatibility, the design of surfaces that do not provoke clotting.

The approaches were chemical and physical. Heparin, the natural anticoagulant, was immobilized on surfaces; hydrophilic polymers such as PEG (polyethylene glycol) were grafted on to resist protein adsorption; surfaces were made smooth, or given a lining of the patient's own endothelial cells. The deeper lesson, established through the 1970s and 1980s, was that the first thing the body "sees" is not the material but a layer of adsorbed protein, and that the composition and conformation of that layer govern everything downstream. This shifted biomaterials thinking from bulk properties toward surface science.

Bioactive materials: making the body respond well

The next turning point inverted the goal. Instead of asking the body to ignore the material, the bioactive paradigm asked the material to elicit a specific, beneficial biological response. The landmark was Bioglass, a calcium–phosphosilicate glass developed by Larry Hench and colleagues in the late 1960s and reported in 1971. Implanted in bone, certain compositions of this glass form a surface layer of hydroxycarbonate apatite—chemically close to bone mineral—and bond directly to living bone rather than being separated from it by a fibrous layer. The same idea appeared in calcium phosphate ceramics and in glass-ceramics, which could be tailored to bond to bone or to be resorbed.

Bioactivity gave the field a new vocabulary: materials could be osteoconductive (guiding bone formation along their surface) or, in some formulations, osteoinductive (stimulating bone formation). It also produced a practical success: bioactive glass and calcium phosphate coatings on metal implants, used to improve fixation. The paradigm's claim was that a material's surface chemistry could be a signal, not merely a boundary.

Degradable and resorbable materials: designing for disappearance

If an implant's job is temporary—a suture, a bone screw, a drug carrier—then leaving it in place forever is a failure mode. The resorbable paradigm, developed mainly from the 1960s onward, designed materials to break down in the body into harmless products at a controlled rate.

The workhorses were the polyesters: polyglycolic acid (PGA), polylactic acid (PLA), and their copolymer PLGA, which hydrolyze in water to lactic and glycolic acid, both normal metabolic products. Their degradation rate could be tuned by composition and molecular weight, and they became the basis of resorbable sutures (marketed from the 1970s) and, later, of controlled-release drug depots and temporary fixation devices. The paradigm's hard problem was matching degradation to healing: a screw that loses strength before the bone has healed fails, and one that lingers too long provokes the same foreign-body response as a permanent implant. The acidic breakdown products can also cause local inflammation in large volumes—a limitation that shaped later designs.

Hydrogels and the soft-tissue problem

Soft tissue is mostly water, and the materials that mimic it are hydrogels—crosslinked polymer networks swollen with water. Their history runs through contact lenses (soft lenses of poly(hydroxyethyl methacrylate), or pHEMA, developed in the 1960s) and wound dressings, but their importance to biomaterials grew as the field turned toward tissue that is soft, hydrated, and mechanically delicate.

Hydrogels made it possible to think about mechanical mimicry: a material whose stiffness and water content resemble cartilage, vitreous, or brain. They also made possible encapsulation of cells and drugs under gentle conditions, since the network forms in water rather than in harsh solvents. The persistent difficulty was strength—conventional hydrogels are weak and tear easily—which drove decades of work on tougher networks, including double-network gels and, later, tough hydrogels with covalent and ionic crosslinking.

Tissue engineering scaffolds: the material as a temporary architecture

The tissue-engineering paradigm, articulated influentially by Robert Langer and Joseph Vacanti in the 1990s, recast the material as a scaffold: a temporary three-dimensional architecture in which cells are seeded or into which they migrate, which guides the formation of new tissue and then degrades away. The scaffold had to satisfy a demanding set of requirements at once—interconnected porosity for cell infiltration and nutrient transport, mechanical properties matching the target tissue, a degradation rate matched to tissue growth, and surface chemistry that cells would attach to.

The materials were largely borrowed from the earlier paradigms: PLGA and other resorbable polyesters, collagen and other natural polymers, and ceramics for bone. The field's characteristic methods were also established here: electrospinning to make fibrous mats resembling extracellular matrix, freeze-drying and porogen leaching to create porous foams, and the use of decellularized tissue as a natural scaffold. The paradigm's central claim was that the body's own cells could be recruited to rebuild tissue if given the right temporary structure—an idea that made the material a participant in biology rather than a passive replacement.

Bioinstructive design and mechanobiology

The scaffold paradigm raised a sharper question: what, exactly, should the material tell the cells? The answer came from mechanobiology—the study of how cells sense and respond to mechanical forces—and from the realization that a material's stiffness, topography, and bound signaling molecules are themselves instructions.

A widely cited demonstration came in 2006, when a group led by Dennis Discher showed that mesenchymal stem cells grown on gels of different stiffness would commit to different lineages: soft gels resembling brain favored neural markers, intermediate stiffness resembling muscle favored muscle markers, and stiff gels resembling bone favored bone markers. The material's physical property, not just its chemistry, was a signal. This, together with the broader finding that cells pull on their substrate and convert that resistance into biochemical signals, made "bioinstructive" design a program: materials decorated with adhesion peptides, growth factors, or enzyme-cleavable crosslinks that cells themselves could remodel. The material became a partner in a conversation, and the design question became which signals to present, in what sequence, and at what mechanical stiffness.

Additive manufacturing and the patient-specific turn

The most recent structural change is in how biomaterials are made. Additive manufacturing—3D printing—builds an object layer by layer from a digital model, and its entry into medicine allowed implants and scaffolds to be shaped to an individual patient's anatomy. Titanium acetabular cups and cranial plates printed to a patient's CT scan are in routine use; printed porous scaffolds with designed pore architecture are a major research direction; and extrusion-based bioprinting, which deposits cell-laden hydrogels, extends the approach to living constructs.

The significance is not only customization. Printing allows internal architecture to be controlled—graded porosity, channels for blood vessels, stiffness that varies across a scaffold—which is exactly the kind of spatial control the bioinstructive paradigm wants. It also changes the economics and regulation of implants, since a one-off device made for one patient sits awkwardly in a system built for mass-produced products.

Where the field stands

Today the paradigms coexist rather than replace one another. Metals and ceramics remain the backbone of load-bearing orthopedics; bioinert and bioactive surfaces are engineered at the nanometer scale; resorbable polyesters dominate temporary fixation and drug delivery; hydrogels and tough soft materials are central to soft-tissue repair and to bioprinting; and the bioinstructive program—stiffness, topography, tethered signals, and degradability tuned to cell behavior—runs through all of them. The open questions are the ones the history keeps returning to: how to make a material that the immune system accepts rather than walls off, how to match degradation to healing in every tissue, how to vascularize thick constructs, and how to test and regulate materials whose designed behavior unfolds over years inside a patient. The field's arc has been from asking the body to tolerate a material to asking a material to take part in the body's own repair—and the hardest part of that arc is still being worked out.

References

  1. Biomaterial (introduction, Introduction), Wikipedia

The frameworks of Biomaterials

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1940-1980

    Inert biomaterials paradigm

    How can a material be made that the body will not react to?

    Fly to its tower in Nousfarer

  2. 1960-Present

    Hydrogel

    How can a water-swollen polymer mimic soft tissue?

    Fly to its tower in Nousfarer

  3. 1965-Present

    Resorbable and degradable materials paradigm

    How can an implant dissolve harmlessly at a controlled rate?

    Fly to its tower in Nousfarer

  4. 1970-Present

    Hemocompatibility and blood–material interface design

    Why does blood clot on synthetic surfaces, and how can it be prevented?

    Fly to its tower in Nousfarer

  5. 1971-Present

    Bioactive materials paradigm

    How can a material actively elicit a beneficial tissue response?

    Fly to its tower in Nousfarer

  6. 1993-Present

    Tissue engineering scaffold paradigm

    How can a temporary architecture guide cells to rebuild tissue?

    Fly to its tower in Nousfarer

  7. 2000-Present

    Additive manufacturing and patient-specific design

    How can implants be fabricated to fit each patient's anatomy?

    Fly to its tower in Nousfarer

  8. 2006-Present

    Bioinstructive design and mechanobiology

    How can mechanical and chemical cues instruct cells to heal?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Inert biomaterials paradigmHydrogelResorbable and degradable materials p…Hemocompatibility and blood–material …Bioactive materials paradigmTissue engineering scaffold paradigmAdditive manufacturing and patient-sp…Bioinstructive design and mechanobiol…

Beyond the field

Where Biomaterials's ideas came from in other fields, and what they led to there: the strongest 12 of 29 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Biomaterials is a planet in Nousfarer

Its city has a tower for each of these 8 frameworks. Land, walk in, and climb one concept at a time.

Land on Biomaterials

Related fields

Fields its ideas are linked to

More in Biomedical Engineering

See where Biomaterials sits on the Map of Human Knowledge